Healthcare / Medical Instruments & SuppliesTaipei Exchange
$94.00
-0.30 (-0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $813.9M · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.7B
P/E
10.5x
↓EV/EBITDA
3.7x
↓ROE
6.9%
↑Gross Margin
23.1%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.3%
FCF CAGR
-23.9%
FCF margin
12.3%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.12B · net income $455.0M · FCF $508.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.12B | $4.12B | $4.55B | $4.39B | $5.00B |
| Net Income | $455.0M | $455.0M | $747.3M | $546.0M | $1.02B |
| EBITDA | $826.0M | $826.0M | $1.23B | $1.01B | $1.62B |
| EPS | 8.91 | 8.91 | 14.70 | 10.74 | 20.05 |
| Gross Margin | 23.1% | 23.1% | 26.7% | 22.2% | 29.5% |
| Operating Margin | 13.9% | 13.9% | 17.6% | 13.7% | 21.4% |
| Net Margin | 11.1% | 11.1% | 16.4% | 12.4% | 20.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.11 | 0.16 |
| Current Ratio | 3.53 | 3.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $508.0M | $508.0M | $860.8M | $813.9M | $1.15B |
| Returns | |||||
| ROE | 6.9% | 6.9% | 11.4% | 8.9% | 16.3% |
| Valuation | |||||
| P/E | 10.55 | 10.55 | 13.23 | 17.64 | 12.57 |
| EV/EBITDA | 3.70 | 3.70 | 6.54 | 8.14 | 7.10 |
| P/B | 0.73 | 0.73 | 1.51 | 1.57 | 2.04 |
| Growth & Yield | |||||
| Revenue Growth | -9.5% | -9.5% | 3.6% | -12.2% | — |
| EPS Growth | -39.4% | -39.4% | 36.9% | -46.4% | — |
| Dividend Yield | 10.1% | 10.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-2.2%
EPS terminal req.
$8.34
Spread vs growth
-37.2%
5Y implied EPS CAGR
2.5%
EPS terminal req.
$10.09
Spread vs growth
-41.9%
10Y implied EPS CAGR
6.2%
EPS terminal req.
$16.25
Spread vs growth
-45.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.0%
Start / end P/E
11.6x → 10.5x
EPS bridge
14.70 → 8.91
Residual
+3.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.